Novartis has decided to stop and discontinue its sponsored hydroxychloroquine (HCQ) clinical trial for Covid-19 due to acute enrollment challenges that have made trial completion infeasible. The recruitment challenge facing our HCQ trial has made it unlikely that the clinical team will be able to collect meaningful data in a reasonable timeframe to determine the effectiveness of HCQ in treating patients with Covid-19. No safety issues have been reported, and there are no conclusions on efficacy from the study.
Novartis will continue to provide the supply of HCQ for ongoing investigator-initiated trials (IITs) and upon government requests, as appropriate, where certain conditions are met, and the medicine is used following a nationally endorsed treatment protocol. Researchers at Novartis continue to monitor health authorities’ ongoing guidance on the further study of HCQ for Covid-19, as well as the decision by the US Food and Drug Administration to stop the emergency use authorization of HCQ for Covid-19 treatment. In addition, ongoing studies involving other Novartis treatments continue, as well as the newly announced support of a potential vaccine. Novartis also continues to collaborate to find answers for Covid-19 through various partnerships with multi-stakeholder external consortia.
